Company news

Natera, Inc. news in 2020

Natera, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Natera Appoints Dr. Monica Bertagnolli to its Board of Directors

November 18, 2020

Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring

November 9, 2020

Natera Reports Third Quarter 2020 Financial Results

November 4, 2020

Natera Announces Third Quarter 2020 Earnings Conference Call

October 27, 2020

Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™

October 1, 2020

Natera Launches Initiative to Transform the Management of Cancer Patients in Organ Transplantation

September 13, 2020

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

September 10, 2020

Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer

September 2, 2020

Natera Announces Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in Early Stage Breast Cancer

August 26, 2020

Natera's Signatera™ Test Receives CE Mark

August 25, 2020

Natera Files Additional Suit Against ArcherDX

August 6, 2020

Natera Reports Second Quarter 2020 Financial Results

August 4, 2020

Natera Announces Second Quarter 2020 Earnings Conference Call

July 28, 2020

Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients

July 6, 2020

Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas

June 21, 2020

Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing

June 17, 2020

Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights

May 31, 2020

Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA

May 25, 2020

Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring

May 18, 2020

Natera and Illumina Settle Patent Dispute

May 17, 2020

Natera Reports First Quarter 2020 Financial Results

May 5, 2020

Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program

May 3, 2020

Natera Announces First Quarter 2020 Earnings Conference Call

April 28, 2020

Natera Prices $250 Million Convertible Senior Notes Due 2027

April 12, 2020

Natera to Offer $250 Million Convertible Senior Notes Due 2027

April 12, 2020

Natera Provides Remote Access to Tests Without Requiring Live Office Visits

March 18, 2020

Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™

March 2, 2020

Natera Reports Fourth Quarter and Year 2019 Financial Results

February 25, 2020

Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call

February 18, 2020

Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

January 12, 2020

Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer

January 8, 2020

Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

January 5, 2020

Decks in 2020